Detalles de la búsqueda
1.
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
J Clin Oncol
; 41(16): 2988-2997, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36977286
2.
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
J Clin Oncol
; 41(16): 2998-3008, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37075276
3.
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Clin Ther
; 31(4): 751-61, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19446148
4.
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.
Clin Rheumatol
; 27(8): 955-60, 2008 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-18180976
5.
Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria.
PLoS One
; 3(3): e1779, 2008 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-18320064
Resultados
1 -
5
de 5
1
Próxima >
>>